Wave Life Sciences is a clinical stage company that develops genetic medicine by using its discovery and drug developing platform PRISM to produce novel stereopure oligonucleotides. The company's focus is on developing oligonucleotides for treating various diseases such as amyotrophic lateral sclerosis, Huntington's disease, Duchenne muscular dystrophy, spinocerebellar ataxia 3, hepatic indications, and retinal diseases. Collaborating with multiple partners worldwide, the company was founded in 2012 and is headquartered in Singapore.